AmCham’s various industry-specific working groups – comprised of the directors of the leading international companies in each respective sector, contributes to a wide range of policy discussions via AmCham position papers, which provide policymakers and relevant stakeholders with genuine industry information and insight.
AmCham submitted comments to the consultation on the Ministry of Health’s proposed regulation prohibiting the marketing of certain food products aimed at children and proposal for a new legal basis to impose penalties for violations of the regulation. AmCham supports the ministry’s goal of improving public health and recognizes that children’s diets are a shared societal responsibility. At the same time, we emphasize the need for a strengthened knowledge base and the importance of a realistic and practical regulation that balances public health and trade implications. Before introducing extensive regulations, AmCham believes it should be assessed whether a strengthened self-regulation system could achieve similar results.
AmCham submitted comments to the follow-up on the National Action Plan for Clinical Studies 2021-2025. This follow-up aligns with AmCham’s commitment to advancing clinical study infrastructure and multinational healthcare investments in Norway. The action plan’s objectives reflect both public ambition and the critical role of private sector engagement to strengthen Norway’s position in clinical research. Our submission focused on the value of clinical studies, innovation, and the importance of effective support mechanisms.
AmCham submitted comments on the Environmental Directorate’s proposed regulatory changes to the Waste Regulations, focusing on extended producer responsibility for certain single-use plastic products. This proposal aligns with EU Directive 2019/904 on reducing environmental impacts of plastic products and aims to prevent pollution, reduce microplastic spread, and support a circular economy. Our submission focused on predictability, cost-effective measures, and public-private cooperation.
AmCham submitted comments to Venstre Representantforslag 8:108 S (2021-2022) on Strengthening Investment in the Norwegian Healthcare Industry. This motion is directly in line with AmCham’s Healthcare Report on fulfilling potential in Multinational Healthcare Investment. It touches upon the important support for industry growth already indicated by the government, and accurately and succinctly represents accompanying private industry support of these goals through each of its recommendations.
AmCham responded to the Hearing on Tendering in Publicly Financed Medicines, arguing against the introduction of a tendering pilot program. We encourage the Norwegian government to carry out a thorough assessment prior to the program’s implementation. This is necessary given the foundational regulations changes the program demands, as well as the broad impact of this program both domestically and within the international ecosystem.
tel.: +47 22 41 50 10 | amcham@amcham.no | Sitemap | Privacy Policy | Designed by Flagship
AmCham © 2024